CoChat

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Background Immunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumour activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma. In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab versus placebo plus pembrolizumab. Methods In this international, randomised, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAF V600 mutant status or consented to BRAF V600 mutation testing during screening. Patients were stratified by PD-L1 expression and BRAF V600 mutation status and randomly assigned (1:1) through a central interactive voice and integrated web response system to receive epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg intravenously every 3 weeks or placebo plus pembrolizumab for up to 2 years. We used block randomisation with a block size of four in each stratum. Primary endpoints were progression-free survival and overall survival in the intention-to-treat population. The safety analysis population included randomly assigned patients who received at least one dose of study treatment.…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30274-8

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 1,000

Metadata

Authors
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., Demidov, L., Robert, C., Larkin, J., Anderson, J. R., Maleski, J., Jones, M., Diede, S. J., & Mitchell, T. C.
Affiliations
  • The University of Sydney (AU)
  • University Hospital Zurich (CH)
  • Angeles Clinic and Research Institute (US)
  • University of Chicago Medical Center (US)
  • Universidad del Desarrollo (CL)
  • Hospital Clínic de Barcelona (ES)
  • Aix-Marseille Université (FR)
  • Seoul National University Hospital (KR)
  • Institut Gustave Roussy (FR)
  • Royal Marsden NHS Foundation Trust (GB)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Incyte (United States) (US)
  • Abramson Cancer Center (US)
Corresponding author
Long, Georgina V
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-08
Volume
20
Issue
8
Pages
1083-1097
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2949375297
Cited by
960
References
26
Citations by year
2026: 108 · 2025: 122 · 2024: 119 · 2023: 141 · 2022: 116 · 2021: 178 · 2020: 141 · 2019: 34
FWCI
50.34
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • University of Sydney
  • National Institutes of Health
  • Incyte
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
epacadostat, pembrolizumab, metastatic melanoma, unresectable melanoma, IDO1 inhibitors, PD-1 inhibitors, immune checkpoint inhibitors, combination immunotherapy, progression-free survival, overall survival, treatment safety, adverse events
MeSH terms
Progression-Free Survival, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Oximes, Sulfonamides, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30274-8
The paper
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., Demidov, L., Robert, C., Larkin, J., Anderson, J. R., Maleski, J., Jones, M., Diede, S. J., & Mitchell, T. C. (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30274-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.